Background:
Major Depression Disorder (MDD) is accompanied by an immune response
characterized by increased levels of inflammatory and immune-regulatory cytokines and stimulation of
indoleamine-2,3-dioxygenase (IDO). There is also evidence that anti-inflammatory drugs may have
clinical efficacy in MDD.
Objective:
This study examined a) IDO in association with interferon (IFN)-γ, Interleukin (IL)-4 and
Transforming Growth Factor (TGF)-β1 in 140 drug-naïve MDD patients and 40 normal controls; and
b) the effects of an eight-week treatment of sertraline with or without ketoprofen (a nonsteroidal antiinflammatory
drug) on the same biomarkers in 44 MDD patients.
Results:
Baseline IDO, IFN-γ, TGF-β1 and IL-4 were significantly higher in MDD patients as compared
with controls. Treatment with sertraline with or without ketoprofen significantly reduced the
baseline levels of all biomarkers to levels which were in the normal range (IDO, TGF-β1, and IL-4) or
still somewhat higher than in controls (IFN-γ). Ketoprofen add-on had a significantly greater effect on
IDO as compared with placebo. The reductions in IDO, IL-4, and TGF-β1 during treatment were significantly
associated with those in the BDI-II
Conclusion:
MDD is accompanied by activated immune-inflammatory pathways (including IDO) and
the Compensatory Immune-Regulatory System (CIRS). The clinical efficacy of antidepressant treatment
may be ascribed at least in part to decrements in IDO and the immune-inflammatory response.
These treatments also significantly reduce the more beneficial properties of T helper-2 and T regulatory
(Treg) subsets. Future research should develop immune treatments that target the immune-inflammatory
response in MDD while enhancing the CIRS.
There is now evidence that major depression is accompanied by lowered serum zinc, an immune-inflammatory biomarker. However, the effect of anti-inflammatory drugs as adjuvant to antidepressants on serum zinc and copper in relation to pro- and anti-inflammatory cytokines are not studied. The aim of the present work is to examine the effects of treatment with sertraline with and without ketoprofen on serum levels of zinc and copper in association with immune-inflammatory biomarkers in drug-naïve major depressed patients. We measured serum zinc and copper, interleukin (IL)-1β, IL-4, IL-6, IL-18, interferon (IFN)-γ, and transforming growth factor (TGF)-β1 in 40 controls and 133 depressed patients. The clinical efficacy of the treatment was measured using the Beck Depression Inventory-II (BDI-II) at baseline and 8 weeks later. In drug-naïve major depressed patients we found significantly reduced baseline levels of serum zinc and copper in association with upregulation of all cytokines, indicating activation of the immune-inflammatory responses system (IRS) as well as the compensatory immune regulatory system (CIRS). Treatment with sertraline significantly increased zinc and decreased copper levels, while ketoprofen did not have a significant add-on effect on zinc but attenuated the suppressant effects of sertraline on copper levels. During treatment, there was a significant inverse association between serum zinc and activation of the IRS/CIRS. The improvement in the BDI-II during treatment was significantly associated with increments in serum zinc coupled with attenuation of the IRS/CIRS. In conclusion, lower serum zinc is a hallmark of depression, while increments in serum zinc and attenuation of the immune-inflammatory response during treatment appear to play a role in the clinical efficacy of sertraline. Intertwined changes in zinc levels and the immune response play a role in the pathophysiology of major depression and participate in the mechanisms underpinning the clinical efficacy of antidepressants.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.